Breast cancer-initiating cells: Insights into novel treatment strategies

Cancers

Volumn 3, Issue 1, 2011, Pages 1405-1425

  Santilli, Guido ^a   Binda, Mara ^a   Zaffaroni, Nadia ^a   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer initiating cells; Drug resistance; Drug targets; Prognosis; Self renewal pathways; Survival pathways

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; BXL 0124; DOFEQUIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; REPARIXIN; SALINOMYCIN; SONIC HEDGEHOG PROTEIN; TRANILAST; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NANOG; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT; WNT PROTEIN; WNT4 PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CELL ISOLATION; CELL RENEWAL; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME METABOLISM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC STABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXIDATION; PHENOTYPE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 79953701955     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3011405     Document Type: Review

References (69)

1. La Vecchia, C.; Bosetti, C.; Lucchini, F.; Bertuccio, P.; Negri, E.; Boyle, P.; Levi, F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann. Oncol. 2009, 19, 79-86.
2. Cardoso, F.; Bedard, P.L.; Winer, E.P.; Pagani, O.; Senkus-Konefka, E.; Fallowfield, L.J.; Kyriakides, S.; Costa, A.; Cufer, T.; Albain, K.S.; ESO-M BC Task Force. International guidelines for management of metastatic breast cancer: Combination vs. sequential single-agent chemotherapy. J. Natl. Cancer Inst. 2009, 101, 1174-1181.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687-1717.
4. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
5. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura, M.J.; Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17, 1253-1270.
6. Glinsky, G.V.; Berezovska, O.; Glinskii, A.B. M icroarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 2005, 115, 1503-1521.
7. Liu, R.; Wang, X.; Chen, G.Y.; Dalerba, P.; Gurney, A.; Hoey, T.; Sherlock, G.; Lewicki, J.; Shedden, K.; Clarke, M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 2007, 356, 217-226.
8. Balic, M.; Lin, H.; Young, L.; Hawes, D.; Giuliano, A.; McNamara, G.; Datar, R.H.; Cote, R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12, 5615-5621.
9. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao. J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11, 259-273.
10. Abraham, B.K.; Fritz, P.; McClellan, M.; Hauptvogel, P.; Athelogou, M.; Brauch, H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005, 11, 1154-1159.
11. Wright, M.H.; Calcagno, A.M.; Salcido, C.D.; Carlson, M.D.; Ambudkar, S.V.; Varticovski, L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10, R10.
12. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
13. Resetkova, E.; Reis-Filho, J.S.; Jain, R.K., Mehta, R.; Thorat, M.A.; Nakshatri, H.; Badve, S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 2010, 123, 97-108.
14. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Tarpin, C.; Diebel, M.; Esterni, B.; Houvenaeghel, G.; Extra, J.M.; Bertucci, F.; Jacquemier, J.; Xerri, L.; Dontu, G.; Stassi, G.; Xiao, Y.; Barsky, S.H.; Birnbaum, D.; Viens, P.; Wicha, M.S. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16, 45-55.
15. Zhou, Z.; Zhang, Z. Cancer stem cells. Models, mechanisms and implications for improved treatment. Cell Cycle 2008, 7, 1370-1370.
16. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumori genic. Cancer Res. 2005, 65, 6207-6219.
17. Lou, H.; Dean, M. Targeted therapy for cancer stem cells: The patched pathway and ABC transporters. Oncogene 2007, 26, 1357-1360.
18. Dontu, G.; Jackson, K.W.; McNicholas, E.; Kawamura, M.J.; Abdallah, W.M.; Wicha, M.S. Role of Notch signalling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004, 6, R605-R615.
19. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65, 5506-5511.
20. Gasparini, P.; Bertolini, G.; Binda, M.; Magnifico, A.; Albano, L.; Tortoreto, M.; Pratesi, G.; Facchinetti, F.; Abolafio, G.; Roz, L.; Tagliabue, E.; Daidone, M.G.; Sozzi, G. Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Lett. 2010, 296, 206-215.
21. Daidone, M.G. Fondazione IRCCS-Istituto Nazionale dei Tumori, Mila, Italy. Unpublished work, 2011.
22. Bourguignon, L.Y.; Spevak, C.C.; Wong, G.; Xia, W.; Gilad, E. Hyaluronan-CD44 interaction with PKC-epsilon promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 2009, 284, 26533-26546.
23. Savarese, T.M.; Strohsnitter, W.C.; Low, H.P.; Liu, Q.; Baik, I.; Okulicz, W.; Chelmow, D.P.; Lagiou, P.; Quesenberry, P.J.; Noller, K.L.; Hsieh, C.C. Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res. 2007, 9, R29.
24. Clarke, R.B.; Spence, K.; Anderson, E.; Howell, A.; Okano, H.; Potten, C.S. A putative human breast stem cells population is enriched for steroid receptor-positive cells. Dev. Biol. 2005, 277, 443-456.
25. Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27, 6120-6130.
26. Liu, S.; Ginestier, C.; Charafe-Jauffret, E.; Foco, H.; Kleer, C.G.; Merajver, S.D.; Dontu, G.; Wicha, M.S. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl. Acad. Sci. USA 2008, 105, 1680-1685.
27. Kritikou, E.A.; Sharkey, A.; Abell, K.; Came, P.J.; Anderson, E.; Clarkson, R.W.; Watson, C.J. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003, 130, 3459-3468.
28. Sansone, P.; Storci, G.; Tavolari, S.; Guarnieri, T.; Giovannini, C.; Taffurelli, M.; Ceccarelli, C.; Santini, D.; Paterini, P.; Marcu, K.B.; Chieco, P.; Bonafè, M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117, 3988-4002.
29. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
30. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
31. Qiao, L.; Xu, Z.L.; Zhao, T.J.; Ye, L.H.; Zhang, X.D. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008, 269, 67-77.
32. Dejmek, J.; Leandersson, K.; Manjer, J.; Bjartell, A.; Emdin, S.O.; Vogel, W.F.; Landberg, G.; Andersson, T. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct decisive roles in breast cancer patients survival. Clin. Cancer Res. 2005, 11, 520-528.
33. Jonsson, M.; Dejmek, J.; Bendahl, P.O.; Andersson, T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 2002, 62, 409-416.
34. Leris, A.C.; Roberts, T.R.; Jiang, W.G.; Newbold, R.F.; Mokbel, K. WNT5A expression in human breast cancer. Anticancer Res. 2005, 25, 731-734.
35. Nakapoulou, L.; Mylona, E.; Papadaki, I.; Kavantzas, N.; Giannopoulou, I.; Markaki, S.; Keramopoulos, A. Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod. Pathol. 2006, 19, 556-563.
36. Lo, P.K.; Mehrotra, J.; D'Costa, A.; Fackler, M.J.; Garrett-Mayer, E.; Argani, P.; Sukumar, S. Epigenic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol. Ther. 2006, 5, 281-286.
37. Veeck, J.; Niederacher, D.; An, H.; Klopocki, E.; Wiesmann, F.; Betz, B;. Galm, O.; Camara, O.; Durst, M.; Kristiansen, G.; Huszka, C.; Knuchel, R.; Dahl, E. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006, 25, 3479-3488.
38. Ezeh, U.I.; Turek, P.J.; Reijo, R.A.; Clark, A.T. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 10, 2255-2265.
39. Bièche, I.; Lerebours, F.; Tozlu, S.; Espie, M.; Marty, M.; Lidereau, R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin. Cancer Res. 2004, 10, 6789-6795.
40. Kubo, M.; Nakamura, M.; Tasaki, A.; Yamanaka, N.; Nakashima, H.; Nomura, M.; Kuroki, S.; Katano, M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004, 64, 6071-6074.
41. Daidone, M.G. Fondazione IRCCS-Istituto Nazionale dei Tumori, Mila, Italy. Unpublished work, 2011.
42. Stylianou, S.; Clarke, R.B.; Brennan, K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66, 1517-1525.
43. Pece, S.; Serresi, M.; Santolini, E.; Capra, M.; Hulleman, E.; Galimberti, V.; Zurrida, S.; Maisonneuve, P.; Viale, G.; Di Fiore, P.P. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 2004, 167, 215-221.
44. Parr, C.; Watkins, G.; Jiang, W.G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumor clinicopathological parameters in human breast cancer. Int. J. Mol. Med. 2004, 14, 779-786.
45. Dievart, A.; Beaulieu, N.; Jolicoeur, P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999, 18, 5973-5981.
46. Reedijk, M.; Odorcic, S.; Chang, L.; Zhang, H.; Miller, N.; McCready, D.R.; Lockwood, G.; Egan, S.E. High-level coexpression of JAG1 and NOTCH 1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65, 8530-8537.
47. Farnie, G.; Clarke, R.B.; Spence, K.; Pinnock, N.; Brennan, K.; Anderson, N.G.; Bundred, N.J. Novel cell culture technique for primary ductal carcinoma in situ: Role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 2007, 99, 616-627.
48. Magnifico, A.; Albano, L.; Campaner, S.; Delia, D.; Castiglioni, F.; Gasparini, P.; Sozzi, G.; Fontanella, E.; Menard, S.; Tagliabue, E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15, 2010-2021.
49. May. C.D.; Sphyris, N.; Evans, K.W.; Werden, S.J.; Guo, W.; Mani, S.A. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 2011, 13, 202.
50. Coradini, D.; Gariboldi, M.; Fedeli, M.; Pierotti, M.A.; Daidone, M.G. Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxif en. Breast Cancer Res. Treat. 2008, 111, 389-390.
51. Van de Vijver, M.J.; He, Y.D.; van't Veer, L.J.; Dai, H.; Hart, A.A.; Voskuil, D.W.; Schreiber, G.J.; Peterse, J.L.; Roberts, C.; Marton, M.J.; et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347, 1999-2009.
52. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea-a paradigm shift. Cancer Res. 2006, 66, 1883-1890.
53. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem-cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66, 9339-9344.
54. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253-1261.
55. Li, X.; Lewis, M.T.; Huang, J.; Gutierrez, C.; Osborne, C.K.; Wu, M.F.; Hilsenbeck, S.G.; Pavlick, A., Zhang, X.; Chamness, G.C.; Wong, H.; Rosen, J.; Chang, J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100, 672-679.
56. Tanei, T.; Morimoto, K.; Shimazu, K.; Kim, S.J.; Tanji, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15, 4234-4241.
57. Aulmann, S.; Waldburger, N.; Penzel, R.; Andrulis, M.; Schirmacher, P.; Sinn, HP. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum. Pathol. 2010, 41, 574-581.
58. Daidone, M.G. Fondazione IRCCS-Istituto Nazionale dei Tumori, Mila, Italy. Unpublished work, 2011.
59. Mimeault, M.; Johansson, S.L.; Vankatraman, G.; Moore, E.; Henichart, J.P.; Depreux, P.; Lin, M.F.; Batra, S.K. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol. Cancer Ther. 2007, 6, 967-978.
60. Mimeault, M.; Mehta, P.P.; Hauke, R.; Henichart, J.P.; Depreux, P.; Lin, M.F.; Batra, S.K. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades. Growth Factors 2007, 25, 400-416.
61. Robertson, F. M; Woodward, W.A.; Pickei, R.; Ye, Z.; Bornmann, W.; Pal, A.; Peng, Z.; Hall, C.S.; Cristofanilli, M. Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer 2010, 10, 2760-2767.
62. Ginestier, C.; Liu, S.; Diebel, M.E.; Korkaya, H.; Luo, M.; Brown, M.; Wicinski, J.; Cabaud, O.; Charafe-Jauffret, E.; Birnbaum, D.; Guan, J.L.; Dontu, G.; Wicha, M.S. CX CR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120, 485-497.
63. Katayama, R.; Koike, S.; Sato, S.; Sugimoto, Y.; Tsuruo, T.; Fujita, N. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci. 2009, 100, 2060-2068.
64. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138, 645-659.
65. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69, 7-11.
66. Prud'homme, G.J.; Glinka, Y.; Toulina, A.; Ace, O.; Subramaniam, V.; Jothy, S. Breast cancer stem-like cel ls are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010, 5, e13831.
67. So, J.Y.; Lee, H.J.; Smolared, A.K.; Paul, S.; Wang, C-X.; Maehr, H.; Uskokovic, M.; Zheng, X.; Conney, A.H.; Cai, L.; Liu, F.; Suh, N. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol. Pharm. 2010, doi:10.1124/mol.110.068403.
68. Marian, C.O.; Cho, S.K.; McEllin, B.M.; Maher, E.A.; Hatanpaa, K.J.; Madden, C.J.; Mickey, B.E.; Wright, W.E.; Shay, J.W.; Bachoo, R.M. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin. Cancer Res. 2010, 16, 154-163.
69. Cripe, T.P.; Wang, P.Y.; Marcato, P.; Mahller, Y.Y.; Lee, P.W. Targeting cancer-initiating cells with oncolytic viruses. Mol. Ther. 2009, 17, 1677-1682.